The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and Type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion
Tóm tắt
The effects of porcine glucose-dependent insulinotropic polypeptide given by continuous intravenous infusion in normal subjects (n=6) and Type 2 (non-insulin-dependent) diabetic patients (n=6) have been investigated. The subjects were studied on 2 separate days after overnight fasts. On each day 25 g of glucose was infused from 0–30 min plus an infusion of either porcine glucose-dependent insulinotropic polypeptide (0.75 pmol·kg−1·min−1) or control solution. During the glucose-dependent insulinotropic polypeptide infusion plasma glucose values were reduced in normal subjects from 30–60 min (p<0.01) and in Type 2 diabetic patients at 45 and 60 min (p<0.05). In the normal subjects insulin concentrations were greater from 10–35 min (p<0.01) following glucose-dependent insulinotropic polypeptide infusion and peak values were increased by 123%. In the Type 2 diabetic patients following glucose-dependent insulinotropic polypeptide infusion insulin levels were increased from 4–40 min (p<0.01) but peak values were only increased by 27%. In the normal subjects C-peptide values were greater from 25–45 min (p<0.01) following glucose-dependent insulinotropic polypeptide infusion and peak C-peptide levels were increased by 82%. In the Type 2 diabetic patients following the glucose-dependent insulinotropic polypeptide infusion C-peptide levels were increased from 6–55 min (p<0.01) and peak values were increased by 20%. Plasma glucose-dependent insulinotropic polypeptide levels were within the physiological post prandial range during the glucose-dependent insulinotropic polypeptide infusion. Glucose-dependent insulinotropic polypeptide is insulinotropic in normal subjects and Type 2 diabetic patients at physiological concentrations and results in improved glucose tolerance. This insulinotropic effect is less marked in the diabetic patients and may represent insensitivity of the B cell to glucose-dependent insulinotropic polypeptide.
Tài liệu tham khảo
McIntyre N, Holdsworth CD, Turner OS (1964) New interpretation of oral glucose tolerance. Lancet 2: 20–21
Brown JC, Otte SC (1978) Gastrointestinal hormones and the control of insulin secretion. Diabetes 27: 782–789
Katz A, Rubenstein AH (1973) Metabolism of proinsulin, insulin and C-peptide in the rat. J Clin Invest 5–12: 1113–1121
Hampton SM, Morgan LM, Tredger JA, Cramb R, Marks V (1986) Insulin and C-peptide levels after oral and intravenous glucose. Diabetes 35: 612–616
Nauck M, Homberger E, Siegel E, Allen R, Eaton R, Ebert R and Creutzfeldt W (1986) Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63: 492–498
Cleator IGM, Gourlay RH (1975) Release of immunoreactive gastric inhibitory polypeptide (IR-GIP) by oral ingestion of food substances. Am J Surg 13: 128–135
Maletti M, Portha B, Carlquist M, Kergoat M, Laburthe M, Marie JC, Rosselin G (1984) Evidence for and characterisation of specific high affinity binding sites for the gastric inhibitory polypeptide in pancreatic beta cells. Endocrinology 115: 1324–1331
Amiranoff B, Vanclin-Jacques N, Labenthe M (1984) Functional GIF receptors in a hamster pancreatic-cell line. In: III: Specific binding and biological effects. Biochem Biophys Res Commun 123: 671–676
Dupre J, Ross SA, Watson D and Brown JC (1973) Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 37: 826–828
Elahi D, Andersen DK, Brown JC, Debas HT, Hershcopf RJ, Raizes GS, Tobin JD and Andres R (1976) Pancreatic alpha and beta cell responses to GIF infusion in normal man. Am J Physiol 237: E185–191
Sarson DL, Wood SM, Holder D, Bloom SR (1982) The effect of glucose dependent insulinotropic polypeptide infused at physiological concentrations of the release of insulin in man. Diabetologia 22: 33–36
Brown JC, Dryburgh JR, Ross SE, Dupre J (1975) Identification and actions of gastric inhibitory polypeptide. Recent Prog Horm Res 31: 487–532
Crockett SE, Mazzaferri EL, Cataland S (1976) Gastric inhibitory polypeptide (GIP) in maturity onset diabetes mellitus. Diabetes 25: 931–935
Ebert R, Frerichs H, Creutzfeldt W (1976) Serum gastric inhibitory polypeptide responses in patients with maturity onset diabetes and in juvenile diabetics. Diabetologia 12: 388 (Abstract)
Ross SA, Brown JC, Dupre J (1977) Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus. Diabetes 26: 525–529
Bloom SR (1975) GIP in diabetes. Diabetologia 2: 334 (Abstract)
Alam MJ, Buchanan KD (1980) Gastric inhibitory polypeptide (GIP) responses in primary diabetes. Regul Pept 1 [Suppl]: 52 (Abstract)
Krarup T, Madsbad S, Moody AJ, Regeur O, Faber K, Holst JJ and Sestoft L (1983) Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed Type 1 (insulin dependent) diabetics. J Clin Endocrinol Metab 56: 1306–1312
Coxe JS, O'Dorisio TM, Cataland S, Crockett SE (1981) Gastric inhibitory polypeptide hypersecretion in diabetes mellitus. Effect of sulphonylurea treatment. J Clin Endocrinol Metab 52: 1002–1005
Salera M, Giacomoni P, Pironi L, Cornia G, Capelli M, Marini A, Benfenati F, Miglioli M, Barbara L (1982) Gastric inhibitory polypeptide release after oral glucose: relationship to glucose intolerance, diabetes mellitus and obesity. J Clin Endocrinol Metab 55: 329–336
Ross SA, Dupre J (1978) Effects of ingestion of triglyceride or galactose on secretion of gastric inhibitory polypeptide and on responses to intravenous glucose in normal and diabetic subjects. Diabetes 27: 327–333
Amland PF, Jorde R, Aanderud P, Burhol PG, Giercksky KE (1985) Effects of intravenously infused porcine GIP on serum insulin, plasma C-peptide, and pancreatic polypeptide in non-insulin-dependent diabetes in the fasting state. Scand J Gastroenterol 20: 315–320
Moody AJ, Jorgensen KD, Thim L (1981) Structure function relationship in porcine GIP. Diabetologia 21: 306 (Abstract)
Wolffbrandt KH, Damm Jorgensen K, Moody AJ, Pedersen PC (1986) The effects porcine GIP on insulin secretion and glucose clearance in the pig. Horm Metabol Res 18: 159–162
Heding LG (1975) Radioimmunological determination of human C-peptide in serum. Diabetologia 11: 541–548
Heding LG (1972) Determination of total serum insulin (IRI) in insulin treated diabetic patients. Diabetologia 8: 260–266
Lauritsen KB, Moody AJ (1978) The response of gastric inhibitory polypeptide (GIP) and insulin to glucose in duodenal ulcer patients. Diabetologia 14: 149–153
Moody AJ, Thim L, Valverde I (1984) The isolation and sequencing of human gastric inhibitory polypeptide (GIP). FEBS Lett 172: 142–148
Service FJ, Hall LD, Westland RE, O'Brien PC, Go VLW, Haymond MW, Rizza RA (1983) Effects of size, time of day and sequence of meal ingestion on carbohydrate tolerance in normal subjects. Diabetologia 25: 316–321
Grapo PA, Reaven G, Olefsky J (1976) Plasma glucose and insulin responses to orally administered simple and complex carbohydrates. Diabetes 25: 741–747
Jones IR, Owens DR, Birtwell AJ, Luzio SD, Davies CJ, Hayes TM (1984) Hormonal and metabolic responses to glucose and meal tests in NIDDM patients. Diabetic Med 2: 163 (Abstract)
Jones IR, Owens DR, Luzio SD, Hayes TM (1986) Glucose dependent insulinotropic polypeptide (GIP) concentrations in non-insulin dependent diabetes mellitus. Diabetic Med 3: 557 (Abstract)
Nauck M, Stockmann F, Ebert R, Creutzfeldt W (1969) Reduced incretin effect in Type 2 (non-insulin dependent) diabetes. Diabetologia 29: 46–52 (Abstract)